RoverMed BioSciences
Saint Cloud
About RoverMed BioSciences
RoverMed develops precision targeted drug delivery technology aimed at delivering life saving drugs to the most challenging diseases in hard to reach places in the body. RoverMed has developed targeted, twenty nanometer nanocapsule technology capable of reaching the most challenging disease sites and delivering cargo – intact – into the nucleus of target cells, regardless of where these cells are located in the body. RoverMed’s nanocapsule technology has been proven, through years of intensive research and development, by Minnesota-based GeneSegues Therapeutics. A precision target drug delivery platform has been developed initially for solid tumor cancers of the head and neck, prostate, and colon. RoverMed is now applying this technology toward a broader spectrum of treatment applications, in partnership with larger drug developers, in order to expand the acceptance, use and impact on a host of new, exciting applications. Our business model includes partnering our drug delivery technology with our partner's drugs to advance novel therapeutics aimed at treating some of the most challenging diseases that are not well served by traditional therapeutic options.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $2.2M
- Funding stage: M&A
- Last round: Series Unknown (Feb 2018)
- Website: rovermed.com
- Phone: 612.437.8836
Industries & Categories
Biotechnology, Health Care, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/rovermed-biosciences-43300 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.